Pubdate: Thu, 14 Jul 2005 Source: Wall Street Journal (US) Section: Pg D3 Copyright: 2005 Dow Jones & Company, Inc. Contact: http://www.wsj.com/ Details: http://www.mapinc.org/media/487 Author: Anna Wilde Mathews and Jennifer Corbett Dooren Bookmark: http://www.mapinc.org/find?232 (Chronic Pain) Bookmark: http://www.mapinc.org/oxycontin.htm (Oxycontin/Oxycodone) PURDUE PHARMA IS ORDERED TO SUSPEND NEW PAINKILLER Purdue Pharma LP agreed to pull its powerful new painkiller Palladone from the market because of evidence that, when taken with alcohol, it could cause serious and sometimes fatal reactions. The Food and Drug Administration, which asked Purdue Pharma to suspend sales of the drug, said it hadn't received reports of major problems since the drug went on the U.S. market in February. The FDA said data from a Purdue Pharma study showed that, when Palladone capsules were combined with even a relatively small amount of alcohol, the mechanism ensuring the drug is released gradually over 24 hours could be disabled. As a result, patients could get the full effects of Palladone's active ingredient, the potent narcotic hydromorphone, all at once, leading to problems including depressed or stopped breathing, coma or death. Even for the lowest marketed dose of the drug, the FDA said, it could prove fatal. The agency said a Purdue Pharma study in 24 healthy men showed that with a low dose of Palladone, concentrations of hydromorphone in the blood could be 5.5 times higher when it was taken with eight ounces of a 40%-alcohol solution. The move is the latest in a series of recent actions by the agency pressing a tough line on drug safety matters. Palladone held "no unique benefit other than its convenience," and the FDA believed that a label warning wouldn't eliminate the risk that the drug might be taken with alcohol, said Robert Meyer, an FDA office director. Palladone already had a strong label warning against the use of alcohol. The agency also said it planned to review other drugs with time-release mechanisms -- beginning with other painkillers, but also including other drugs -- to determine whether there could be similar problems when they interact with alcohol. Purdue Pharma said about 11,500 patients had been prescribed Palladone, which was being rolled out gradually in the U.S. market to reduce the risk of abuse, but a sales figure wasn't immediately available. For closely held Purdue Pharma, the suspension is a serious blow. The company counted on Palladone to replace its blockbuster drug OxyContin, which faces generic competition. OxyContin, also a painkiller, was widely abused by people who deliberately disabled its time-release structure to get a high. The company said it might try to bring Palladone back for use in restricted settings, such as hospitals, and also was working to reformulate it to eliminate the problem with alcohol. A spokesman for Purdue Pharma said the FDA's call for a market suspension was "unanticipated," but the company "complied with their request." Purdue Pharma submitted data to the agency from human tests with alcohol last November, before the drug went on the market, and believed the label warnings "would be sufficient," the spokesman said. The company said it submitted new data to the FDA in June from a later test, but it was told this wasn't the basis for the suspension request. The tests were done voluntarily as part of Purdue Pharma's efforts to pinpoint ways the drug might be abused. The FDA's Dr. Meyer said the data from human tests with alcohol that the agency received before Palladone went on the market were preliminary. The FDA got final results later and wanted to take action before the drug was widely available, he said. Though lab tests had shown there was a potential for Palladone's time-release to be disabled when exposed to alcohol, he said, the agency was surprised at the serious side effects when people took both the drug and alcohol. - ---- Gary Fields contributed to this article. - --- MAP posted-by: Beth